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Antigen‑specific immunotherapy 
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in the treatment of experimental 
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Type 1 diabetes is an autoimmune disease caused by the destruction of the insulin‑producing β‑cells. 
To revert type 1 diabetes, the suppression of the autoimmune attack should be combined with a 
β‑cell replacement strategy. It has been previously demonstrated that liraglutide, a glucagon‑like 
peptide‑1 receptor agonist, restores β‑cell mass in type 1 diabetes, via α‑cell transdifferentiation 
and neogenesis. We report here that treatment with liraglutide does not prevent type 1 diabetes 
in the spontaneous non‑obese diabetic (NOD) mouse model, but it tends to reduce leukocytic islet 
infiltration. However, in combination with an immunotherapy based on tolerogenic liposomes, it 
is effective in ameliorating hyperglycaemia in diabetic NOD mice. Importantly, liraglutide is not 
detrimental for the tolerogenic effect that liposomes exert on dendritic cells from patients with 
type 1 diabetes in terms of membrane expression of molecules involved in antigen presentation, 
immunoregulation and activation. Moreover, the in vivo effect of the combined therapy was tested in 
mice humanised with peripheral blood mononuclear cells from patients with type 1 diabetes, showing 
no adverse effects in leukocyte subsets. In conclusion, the combination therapy with liraglutide and a 
liposome‑based immunotherapy is a promising candidate strategy for type 1 diabetes.
Abbreviations
T1D  Type 1 diabetes
aGLP-1  Analog glucagon-like peptide-1
NOD  Non-obese diabetic mouse
Type 1 diabetes (T1D) is a metabolic disease caused by the autoimmune destruction of the insulin-producing 
pancreatic β-cells. Currently, there is no cure nor prevention for the disease and subjects with T1D need exog-
enous insulin administration to survive. However, this treatment does not lead to continuous normoglycaemia 
and may often produce events of hyper- and hypoglycaemia. Patients with T1D display important associated 
complications—such as neuropathy, nephropathy and retinopathy—that, together with episodes of glycaemia 
dysregulation, worsen their quality of life and may shorten their  lifespan1.
At present, single immunotherapies that have been successful in experimental models have failed in  humans2. 
On the other hand, autologous regenerative strategies, by recovering β-cell mass, are not able to ameliorate the 
disease due to the chronic autoimmune process. Given that, there is an urgent need for novel therapies combin-
ing the regeneration of endogenous β-cells and the arrest of the autoimmune reaction against β-cells. Combined 
therapies using different strategies must be designed for human use. There is a clinical trial already completed in 
 humans3, which consists of the administration of GAD-aluminium conjugate as  immunotherapy4 and  GABA5 
as a regenerative agent (NCT02464033). This resulted in a decrease in daily insulin requirements from baseline 
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to 12 months and the improvement of residual β-cell function by means of C-peptide secretion (a product of 
proinsulin processing). Additionally, a more recent combined strategy—consisting of anti-IL21 and liraglutide—
resulted in the restoration of normoglycaemia in diabetic  mice6. On the one hand, the administration of anti-
IL21 achieved normoglycaemia in some diabetic mice. On the other hand, liraglutide, a commercially available 
drug for type 2 diabetes, contributed to the recovery of the β-cell mass. Because anti-IL21 has systemic effects 
in the immune system, antigen-specific immunotherapies could be safer and help to overcome the side-effect 
issues derived from total immunosuppression. All these data indicate that combined therapies both targeting 
the autoimmune attack and promoting β-cell regeneration could result in a greater beneficial outcome for the 
treatment of T1D.
Our previous work demonstrated the ability of apoptotic β-cells to induce self-tolerance through efferocyto-
sis by dendritic cells (DCs), thus preventing T1D in the non-obese diabetic (NOD) mouse  model7. For clinical 
application, β-cell apoptotic cells were mimicked using nanotherapeutic tools. Liposomes, lipidic vesicles with 
an aqueous core, were designed with phosphatidylserine (PS) in the membrane and encapsulating insulin A and 
B chains (PSAB-liposomes). PSAB-liposomes prevented T1D in the NOD  mice8,9 by inducing tolerogenic DCs. 
Furthermore, this tolerogenic effect was also validated in human DCs from subjects with  T1D10,11. With the aim 
to combine this immunotherapy with a regenerative strategy, we previously performed a Drug Repurposing 
analysis to search for already-existing compounds able to promote β-cell regeneration. Drug Repurposing has 
the advantage to propose novel uses for compounds existing in the market and overcomes the safety issues. The 
analysis identified liraglutide, an agonist of GLP1 (aGLP1), as a regenerative  drug12. In fact, liraglutide admin-
istration ameliorated hyperglycaemia in immunodeficient NOD-Scid  IL2rg-/- (NSG) mice rendered diabetic by 
Streptozotocin. This improvement correlated with the appearance of bihormonal  insulin+glucagon+ cells and 
 insulin+ cells in the ductal  areas12. Previous studies demonstrated the ability of aGLP1 to induce transdifferentia-
tion of glucagon-producing α-cells into β-cells13. Furthermore, aGLP1 induce β-cell proliferation through the 
inhibition of DYRK1A gene  expression14. Ongoing clinical trials aim to assess the effect of liraglutide in subjects 
with T1D (NCT02617654 and NCT02516657).
Taking all this information into account, an experimental combined therapy consisting of an immunotherapy 
based on PSAB-liposomes to arrest autoimmunity and liraglutide to promote β-cell regeneration was designed. 
Here we show that this strategy is able to ameliorate hyperglycaemia in the spontaneous model of autoimmune 
T1D, the NOD mice. Importantly, we also show for the first time that liraglutide does not alter the tolerogenic 
effect of the immunotherapy in DCs from human adult patients with T1D. Additionally, the combined therapy 
does not appear detrimental for T lymphocyte subsets in a humanised mouse model. Investigation of combined 
therapies to restore tolerance and to allow the reestablishment of β-cell mass should continue to completely 
reverse T1D in a clinical setting.
Results
Liraglutide accelerates the onset of T1D in NOD mice. Liraglutide has a regenerative effect on β-cells, 
which might alter the development of T1D. To assess their impact on the onset of the disease, NOD mice (n = 7) 
were treated with three doses of 1 mg/kg of liraglutide on alternate days during the prediabetic period (8 weeks 
old). Sham group (n = 12) was treated with PBS. liraglutide treatment significantly accelerated T1D onset when 
compared to sham group. Mice from the sham group developed the disease from the age of 16.4 weeks and with 
an incidence of 58.33% at 25 weeks of age. Treated mice developed T1D starting at 9.71 weeks of age and reach-
ing an incidence of 57.14% at 25 weeks of age (Fig. 1A). No significant differences in terms of incidence were 
found between both groups at the end of the experiment.
Insulitis score was determined at the end of the follow-up period in non-diabetic mice. In mice treated with 
liraglutide, 62% of the islets remained non-destructed –insulitis free or with peri-insulitis—, whereas only 40% 
of the islets were non-destructed in the sham group (Fig. 1B,C). These differences are statistically significant, 
pointing to a strong difference in the proportion of each type of insulitis between treated and non-treated animals. 
Altogether, this data supports the hypothesis that a regenerative agent may accelerate T1D onset by exacerbating 
the autoimmune reaction.
Given that liraglutide can induce the formation of pseudoislets arising from the ducts 12, hereinafter called 
neoislets, insulitis score was determined for both neoislets and mature islets. Neoislets show an increased insulitis 
score in mice treated with liraglutide when compared to control mice, probably promoted by the β-cell regen-
erative effect of liraglutide in the ducts. On the opposite side, mature islets remain less affected by insulitis in 
liraglutide-treated mice than in controls (Supp. Figure 1).
Liraglutide combined with liposome‑based immunotherapy ameliorates hyperglycaemia in 
NOD mice. Our previous results on the effect of liraglutide in regenerating β-cell  mass12 led us to combine 
this drug with a PS-liposome based immunotherapy, which restores β-cell tolerance. NOD mice were assigned 
to treatment groups—sham, liraglutide, liposomes or combined—as soon as T1D was detected (Fig. 2A). Age 
and glycaemia at T1D onset were similar between groups and all mice included in the experiment developed 
T1D between 12 and 25 weeks of age. Liraglutide monotherapy did not ameliorate hyperglycaemia in mice with 
T1D, despite one mouse transiently achieved normoglycaemia at day 3 and immediately returned to hypergly-
caemia. PSAB-liposome immunotherapy partially ameliorated blood glucose levels, but glycaemia was always 
maintained higher than 270 mg/dL. Importantly, the combined therapy resulted in a significant amelioration of 
glycaemia in 3 of 6 NOD mice (both the responders and non-responders are presented in the graph). Moreover, 
this group has a significant reduction on the glycaemia area under the curve when compared with sham and 
PSAB groups (Fig. 2B), correlating with an improvement in survival compared to the sham group and group 
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treated only with PSAB-liposomes. These responder mice showed a tendency, although non-significant, to dis-
play lower blood glucose levels at T1D onset when compared to non-responders (Fig. 2C).
Liraglutide does not interfere with the tolerogenic ability of liposomes in human DCs. In 
order to identify possible interactions between the two parts of the combined therapy, DCs from patients with 
T1D were exposed to liraglutide and to PS-liposomes and analysed by flow cytometry (Supp. Figure  2). As 
expected, iDCs acquired a tolerogenic phenotype when treated with PSAB-liposomes (Fig. 3) in terms of CD36, 
TIM4, CD49d, HLA Class I, HLA Class II, CD54, CD40, CD86, CD25, CCR7, PD-L1, CXCR4, and TLR2, in 
comparison to mDCs. Liraglutide alone was not able to modify iDC membrane expression of these molecules 
except for an increase in HLA Class I and CCR7. Importantly, the treatment of DCs with the combination of lira-
glutide and PSAB-liposomes resulted in a phenotype identical to tolerogenic treatment with PSAB-liposomes 
in terms of CD36, TIM4, CD49d, HLA Class I, HLA Class II, CD54, CD40, CD86, CD25, CCR7, CXCR4, and 
TLR2. Interestingly, liraglutide in combination with PSAB-liposomes increased the expression of PD-L1 in DCs 
when compared to PSAB-liposomes monotherapy, reinforcing the tolerogenic potential of DCs. These changes 
were predominantly driven by PSAB-liposomes due to their tolerogenic potential as  described10. Of note, PSAB-
liposomes alone induce changes in the membrane expression of these molecules, even in absence of liraglutide, 
that support a tolerogenic role when compared to mDCs and iDCs.
Figure 1.  Effect of liraglutide in pre-diabetic NOD mice. (A) Incidence of diabetes (%) in NOD mice (female) 
treated with liraglutide (Lira, squares, n = 7) or PBS (Sham, triangles, n = 12). No significant differences in 
T1D incidence were found between groups (Mantel-Cox Log-Rank). Significant differences in the age of the 
onset were found between Lira and Sham groups (*p < 0.05, Mann–Whitney test). (B) Percentage of islets in 
each of the infiltration categories, in sham and liraglutide treated groups (n = 3/group): White = 0, no insulitis; 
Dotted = 1, peri-insular; Striped = 2, mild insulitis (< 25% of the infiltrated islet); Squared = 3, 25–75% of the islet 
infiltrated; Black = 4, > 75% islet infiltration. Significant differences were found between groups (*p < 0.05, Chi-
square test). (C) Representative images of insulitis in islets from H/E-pancreatic cryostat sections (5 μm) from 
the two groups. Scale bars represent 100 μm.
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The transcriptional changes induced in DCs from patients with T1D by the combined therapy 
point to a tolerogenic effect. In order to determine if liraglutide altered the previously described tolero-
genic effect of PSAB-liposomes in human  DCs10, RNA-seq analysis was performed in DCs from four patients 
with T1D. Their phagocytosis capability was confirmed by flow cytometry using fluorescent liposomes. After 
4  h of co-culture, 72.83 ± 9.27% (mean ± SD) of DCs were positive for fluorescent signal. RNA integrity was 
determined for each sample, RIN 9.38 ± 0.23 (mean ± SD) being optimal for RNA-seq experiment. Bioinformat-
ics analysis of the RNA-seq revealed 179 differentially expressed genes when comparing iDCs and PSAB-DCs 
(adjusted p value < 0.05 and Log2 of fold change > or < 1.2). Of these 179 genes, 142 (79.33%) were downregu-
lated and the remaining 37 (20.67%) were upregulated, and 152 corresponded to protein-coding genes. The 
comparison between iDCs and combined therapy (liraglutide + PSAB-liposomes) displayed 24 differentially 
expressed genes (adjusted p value < 0.5). Of these 24 genes, 7 (29.16%) were downregulated and the remaining 
17 (70.84%) were upregulated, and finally 21 corresponded to protein-coding genes. In both cases, the gene 
expression was modulated toward a similar profile in DCs exposed to both conditions. Taking into account the 
genes with identical altered expression were found in both analysis (Fig. 4A), three of them were validated by 
qRT-PCR (Fig. 4B).
Figure 2.  Effect of liraglutide in diabetic NOD mice. (A) 2 h fasting blood glucose levels (mg/dL) in diabetic 
NOD mice treated with either PBS (Sham, red, n = 9), PSAB-liposomes (PSAB, grey, n = 6), liraglutide (Lira, 
green, n = 6) or combined (PSAB + Lira, blue, n = 6). Filled area corresponds to normal blood glucose levels 
in NOD mice. (B) Area Under the Curve (AUC) of the graph in (A) at day 10, when all mice of Sham, PSAB, 
and combined groups remain alive. Only responder mice are represented in the combined group. Results are 
expressed as mean ± SD. Differences were found between Sham and PSAB (*p < 0.05, Mann–Whitney test) and 
between Sham and combined therapy (**p < 0.01, Mann–Whitney test). (C) Stratification of responders (black 
squares) and non-responders (white circles) in the group treated with combined therapy regarding the age 
(weeks) and blood glucose levels (mg/dL) at the onset.
5
Vol.:(0123456789)
Scientific Reports |        (2020) 10:18927  | https://doi.org/10.1038/s41598-020-76041-1
www.nature.com/scientificreports/
Figure 3.  Combined therapy regulates dendritic cell (DCs) phenotype. Relative CD36, TIM4, CD49d, HLA-
ABC, HLA-DR, CD54, CD40, CD86, CD25, CCR7, PDL-1, CXCR4 and TLR2 membrane expression in DCs 
(n = 7) obtained from adult subjects with T1D. Results are mean ± SD. Significant differences were found when 
comparing culture conditions (*p ≤ 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, Mann–Whitney test).
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The combined therapy does not alter human leukocyte subsets in humanised mice. To fur-
ther investigate the short-term effects of the combined therapy in human leukocyte subsets, NSG mice human-
ised with PBMCs from patients with T1D were exposed to the combined therapy and monitored for 4 weeks. 
No alterations in leukocyte counts or percentage were found when comparing treated mice to control group 
(Fig. 5A). The number and percentages of T lymphocytes (both  CD4+ and  CD8+) were not altered by the com-
bined therapy (Fig. 5B,C). Similarly, the number and percentages of memory regulatory T cells (mTreg) cells 
were similar to the control group during the follow-up (Fig. 5D).
Discussion
The present study shows that a combined therapy consisting of a regenerative drug and a liposome-based 
immunotherapy—PSAB-liposomes and liraglutide—can ameliorate hyperglycaemia in the spontaneous model 
of autoimmune diabetes, the NOD mouse. In fact, 50% of the treated animals respond to the treatment. First, 
the effects of liraglutide as a regenerative agent in autoimmune diabetes were assessed by its administration in 
prediabetic NOD mice. Liraglutide administration resulted in an acceleration of the onset but without altering 
the incidence of diabetes. These results fit well with a previous study showing that liraglutide did not prevent or 
delay the onset of the disease in NOD  mice6. It is reasonable to speculate that the here reported acceleration of 
T1D onset can be due to the increase in β-cell autoantigens exposure/release induced by liraglutide in a model 
Figure 4.  Gene expression analysis of human DCs co-cultured with PSAB-liposomes and combined therapy. 
(A) List of differentially expressed genes in both PSAB and combined groups in comparison to control 
conditions, showing  log2 of Fold Change and adjusted p-value. (B) Relative gene expression of 3 selected genes 
from A) (FOS, ABCA, CD1D) analysed by qRT-PCR. Gene expression was normalized to GAPDH. Bars show 
the mean ± S.D. of the Log2 of FC using basal transcription as standard value (Wilcoxon test). Validation of the 
differential expression of three selected genes from A) (FOS, ABCA, CD1D) by quantitative RT-PCR (n = 3). 
Results are mean ± SD.
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Figure 5.  In vivo effect of the combined therapy in PBMC-humanised NSG mice. Total counts (left) and 
percentage (right) of human cells at the starting point (in patients), in mice from week 1 (w1) to week 4 (w4) 
post-transplantation and at the endpoint (day 30 of treatment, final). (A) Data of human  CD45+ cells. (B) Data 
of human  CD3+CD4+ cell subset. (C) Data of human  CD3+CD8+ cell subset. (D) Data of human memory T 
regulatory cells (mTreg) subset, identified as  CD3+CD4+CD127lowCD25+CCR4+CD45RO+. Data refers either to 
patients (n = 3), combined (n = 7) or control (n = 3) group.
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with active autoimmunity. This could be due to the fact that neoislets increase the availability of autoantigens—
at least  insulin12—that accelerate the autoimmune attack and actively recruit lymphocytes. Overall, these data 
would not only explain the acceleration in the onset of diabetes but also suggest that regenerative agents like 
liraglutide are not efficient in blocking an autoimmune attack and thus would need to be combined with an 
immunotherapy to restore β-cell tolerance in T1D. An interesting point is that previous studies with combined 
therapies including liraglutide did not observe β-cell  proliferation6, but our previous results demonstrated that 
liraglutide is involved in β-cell replacement, mainly by induction of bihormonal  (glucagon+insulin+) cells and 
from insulin-producing cells in the  ducts12.
In view of this, a therapy was designed by combining the administration of PSAB-liposomes to arrest 
 autoimmunity8,9 prior to liraglutide treatment to promote β-cell  regeneration12 in diabetic NOD mice. This 
strategy resulted in the amelioration of hyperglycaemia in 50% of the treated mice, with some even reaching nor-
moglycaemia. The improvement in the blood glucose levels was transient and mice became hyperglycaemic again 
after the withdrawal of liraglutide. This phenomenon was previously observed upon liraglutide administration 
in diabetic immunodeficient  mice12, suggesting that this drug may be necessary for maintaining physiological 
β-cell function. However, it would be of interest to explore further modifications of the current approach such as 
dosages and administration time-points. Intriguingly, the stratification between responders and non-responders 
showed that those developing T1D with lower glycaemia at the onset were prone to be responders independently 
of the age. This may indicate that, as  proposed15, residual β-cell function is a key feature to be considered in the 
design of combined therapies. It would be of relevance to further expand these observations to other models of 
autoimmune diabetes, like the inducible RIP-B7.1 mouse  model16.
Hence, to determine if liraglutide affected the immunoregulatory effects of PSAB-liposomes, DCs from 
human subjects with T1D were exposed in vitro to both products. In summary, PSAB-liposomes can induce a 
tolerogenic phenotype in DCs on their own and even combined with liraglutide. This is relevant data because it 
demonstrates that liraglutide does not alter the tolerance achieved by PSAB-liposomes phagocytosis in DCs. As 
expected, liraglutide per se was not able to induce phenotypic alterations in iDCs. This is a particular feature of 
the combined therapy since the regenerative agent does not interfere with the immunotherapy in terms of the 
arrest of autoimmunity. The question about liraglutide affecting the tolerogenic properties of DCs treated with 
PSAB-liposomes was also addressed at the gene expression level. RNA-seq experiments revealed that the main 
gene alterations related to tolerance were found in DCs both with and without liraglutide treatment. Further 
research is still needed at the transcriptomics level to find a robust and strong genetic signature by both increas-
ing the sample size and by exploring different time-points of co-culture.
Finally, the establishment of a humanised mouse model by injecting PBMCs from adult subjects with T1D 
in immunocompromised NSG mice enabled us to study the effect of the combined therapy in a broader range 
of human immune cells. No detrimental effect of the combined therapy in the different subsets of human T lym-
phocytes was detected. The poor, almost null, engraftment of B lymphocytes and NK cells limited the outcome 
of this experiment. It would be interesting to evaluate the combined therapy in other humanisation models, 
especially if they can develop diabetes, to achieve a clearer picture of the effects of the combined therapy and 
smooth its way for a clinical translation.
Currently, there are other combined therapies in the experimental field comprising liraglutide as a regenera-
tive  drug6. The main disadvantage in this approach is the use of anti-IL21 as immunotherapy, given that it is a 
systemic immunosuppressive agent. Other immunosuppressive agents totally ablating the immune system have 
proven useful in the arrest of autoimmunity in T1D and even in the reversal of the  disease17,18, but one would 
have to assume the side effects related to immunosuppression as  well19. In that case, it would be much more 
advantageous to focus on antigen-specific therapies targeting specifically the autoimmune reaction against the 
insulin-producing β-cells.
Further studies are required to ameliorate and fully characterise the effect of the here presented combined 
therapy. New schedules of administration should be explored in order to gain insights into the amelioration of 
hyperglycaemia upon different dosages and time-points of treatment. Additionally, it would be of interest to 
evaluate the effect of the combined therapy in other murine models of the disease, such as those induced by 
diabetogenic T cell  transfer20.
In conclusion, the combination therapy consisting of PSAB-liposomes and liraglutide is a strategy that can 
ameliorate hyperglycaemia in half of the mice with overt T1D. Moreover, the regenerative effect of liraglutide 
does not interfere with the tolerogenic consequences of PSAB-liposomes in the human immune system. Despite 
additional research is still needed to explore the regenerative potential of liraglutide, the combined therapy could 
be useful for the treatment of T1D.
Methods
Liposome manufacturing. Liposomes consisted of 1,2-dioleoyl-sn-glycero3-phospho-L-serine (sodium 
salt) (DOPS, Lipoid, Steinhausen, Switzerland) and 1,2-didodecanoyl-sn-glycero-3-phosphocholine (DLPC, 
Lipoid), and cholesterol (CH, Sigma Aldrich, Saint Louis, MO, USA). Liposomes were generated encapsulating 
the murine or human insulin A and B chains (PSAB-liposomes) (Table 1) using the thin film hydration method 
from the lipid mixture, at a final lipid concentration of 30 mM, as  described8–10.
Mice and treatment. NOD mice were bred in our own facility and kept under specific pathogen-free con-
ditions in a 12 h dark/12 h light cycle provided with food and water ad libitum. Mice with either successive 2 h 
fasting blood glucose levels higher than 250 mg/dl or with a measure higher than 300 mg/dl were considered 
diabetic. For prevention experiments, prediabetic NOD females—8 weeks-old—were injected with 3 doses of 
either PBS (Sham) or liraglutide (Lira, 1 mg/kg of body weight) biweekly. For treatment experiments, NOD mice 
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with overt diabetes—12 to 25 weeks-old—were treated daily s.c. only with liraglutide throughout the experiment 
(Lira, n = 6), only with i.p. PSAB-liposomes at days 1, 3 and 7 (PSAB, n = 6), combining i.p. PSAB-liposomes at 
days 1, 3 and 7 with daily s.c. liraglutide from day 4 to 30 (combined group) (PSAB + Lira, n = 6). A sham group 
was included by treating mice daily s.c. with PBS (Sham, n = 6). Mice were monitored biweekly for fasting glu-
cose levels. Mice were euthanised when blood glucose was higher than 600 mg/dL for ethical reasons. At the end 
of the follow-up, mice were euthanised by cervical dislocation and pancreases were harvested and snap-frozen 
in an isopentane/cold acetone bath.
Insulitis score. Pancreases from non-diabetic animals (n = 3) of the incidence study at 25 weeks of age were 
used to determine the insulitis score. Non-overlapping cryosections of 5 μm were obtained and stained with 
haematoxylin and eosin. A double-blind analysis was performed by independent observers. A minimum of 40 
islets per animal was scored to determine the degree of leukocyte infiltration (insulitis), as previously described 
21: 0, no insulitis; 1, peri-insular; 2, mild insulitis (< 25% of the islet infiltrated); 3, 25–75% of the islet infiltrated; 
4, > 75% islet infiltration.
Patients. Adult patients with T1D (n = 13, Table  2) were included in the study. All patients fulfilled the 
diagnosis criteria for T1D. The inclusion criteria were 18–45 years of age and a normal body mass index (BMI, 
18.5–30 kg/m2). Exclusion criteria were being under immunosuppressive or anti-inflammatory treatment, or 
undergoing pregnancy. All study participants gave informed consent, and the study was approved by the Com-
mittee on the Ethics of Research of the Germans Trias i Pujol Hospital.
Generation of human DCs. Peripheral blood mononuclear cells (PBMCs) were obtained from 50 ml blood 
samples of adult patients with T1D (n = 7) after Ficoll Paque density gradient centrifugation (GE Healthcare, 
Marlborough, USA). Monocytes were isolated using the EasySep Human CD14 Positive Selection Kit (STEM-
CELL Technologies, Vancouver, Canada) and cultured with IL-4 and GM-CSF as described 10 to derive DCs. 
After 6 days of culture, DC differentiation yield was assessed by CD11c-APC staining (Immunotools, Friesoythe, 
Germany) using flow cytometry (FACS Canto II, BD Biosciences, San Jose, USA). The negatively selected frac-
tion of PBMCs was cryopreserved in Foetal Bovine Serum (ThermoFisher Scientific, Waltham, MA, USA) with 
10% dimethylsulfoxide (Sigma-Aldrich).
Effects of the combined therapy in human DCs. DCs from patients with T1D (n = 7) were co-cultured 
with 1 mM PSAB-liposomes (PSAB-DC), 1000 nM Lira (Lira-DC) or combined (PSAB + Lira DC) for 24 h in the 
presence of 20 μg/ml human insulin (Sigma-Aldrich). DCs were cultured with 20 μg/ml human insulin (Sigma-
Aldrich) to obtain immature DCs (iDCs) and adding a cytokine cocktail [1000 IU/ml TNFα and 2000 IU/ml 
IL-1β (Immunotools) and 1 μM Prostaglandin  E2 (Cayman Chemical, Ann Arbor, USA)] to obtain mature DCs 
(mDC). To assess DCs phenotype, CD25-PE, CD86-FITC, HLA ABC-FITC, HLA DR-FITC, CD14-PE and 
CD40-APC (Immunotools), CD36-APCCy7, TIM4-APC, CD54-PECy7, TLR2-FITC, CXCR4-APCCy7, CCR2-
APC, PD-L1-PECy7, ILT3-PECy7 (Biolegend, San Diego, USA) and CCR7-PECy7 (BD Biosciences) monoclo-
nal antibodies were used to determine their membrane expression. All DCs conditions from the same patient 
were analysed at the time. All MFI groups were normalized to the MFI of mDCs.
RNA‑seq. DCs from four patients with T1D were cultured in basal conditions (iDCs), with 1 mM PSAB-
liposomes (PSAB-DC), 1000 nM Lira (Lira-DC) or combined (PSAB + Lira DC) for 4 h. Cells were then har-
vested from culture wells with Accutase (eBioscience, San Diego, CA, USA). Viability and DC percentage were 
Table 1.  Features of the liposomes used in the study. The subindex refers to the position of the query sequence 
to the protein. Data are expressed as mean ± SD. PS phosphatidylserine, A insulin A chain, B insulin B chain. 
a These peptides correspond to the whole A or B chains of the insulin peptides.
Liposome Peptide Specie Diameter (nm)
Polydispersity index 
(PdI) ζ-potential (mV) Encapsulation (%)
mPSA-lipos Insulin90–110 (A chain) Mus musculus 712 0.364 − 46.6 32.29
mPSB-lipos Insulin25–54 (B chain) Mus musculus 628 0.325 − 44.9 89.63
hPSA-lipos Insulina (A chain) Homo sapiens 690 ± 29 0.40 ± 0.28  − 38.57 ± 6.76 39.74 ± 22.10
hPSB-lipos Insulina (B chain) Homo sapiens 788 ± 264 0.52 ± 0.42  − 37.50 ± 7.16 93.19 ± 0.92
Table 2.  Data from the patients included in the peripheral blood collection. Data presented as mean ± SD. 
BMI body mass index.
N Gender (M/F) Age (years) BMI Age at onset (years) HbA1c (%)
13 3/13 26.7 ± 4.5 22.2 ± 2.4 13.9 ± 9.6 7.3 ± 0.9
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assessed by flow cytometry (FACS Canto II, BD Biosciences) after staining with 7aad (BD Biosciences), annexin 
V-PE and CD11c-APC (Immunotools). RNA was obtained using the RNeasy Micro Kit (QIAGEN, Hilden, Ger-
many) following the manufacturer’s instructions, and RNA integrity was assessed by capillary electrophoresis in 
the TapeStation 2200 instrument (Agilent Technologies Inc., Santa Clara, CA, USA). Thus, 500 ng of total RNA 
was used to prepare the library. Ribosomal RNA (rRNA) was depleted through oligo-dT binding (mRNA Mag-
netic Isolation, New England Biolabs). Strand-specific libraries were made using the NEBNext Ultra II Direc-
tional RNA LibPrep kit (New England Biolabs), and the quality was evaluated again with TapeStation 2200 
(Agilent Technologies Inc), and quantity, with KAPA Library quantification kit (Roche, Mannheim, Germany). 
RNA sequencing was performed using an Illumina sequencer (Illumina, San Diego, CA, USA) in a sequencing-
by-synthesis protocol consisting of 2 × 75 cycles with 20 million reads. The differential gene expression analysis 
was performed using the DESeq2  algorithm22. Genes with an adjusted p-value < 0.5 and Log2 of fold change > 1.2 
were considered upregulated, whereas those with Log2 of fold change < 1.2 were considered downregulated. 
Experimental data have been uploaded into the European Nucleotide Archive (EBI, https ://www.ebi.ac.uk/ena; 
accession number: GSE144348). Confirmation through qPCR was performed in an independent cohort of 3 
patients as previously described 10,11.
Humanised mice. Normoglycaemic immunodeficient NSG mice at 8 weeks of age were humanised i.p. with 
 107 PBMCs from three different adult subjects with T1D. PBMCs were obtained Ficoll Paque density gradient 
centrifugation (GE Healthcare) as aforementioned. At day 13 after injection, a blood sample (50 µl) was obtained 
from the tail of each mouse and stained for both human and murine CD45 (BD Biosciences). All mice with more 
than 10% of human/murine CD45 chimerism at day 13 were injected either with PBS (n = 3) or the combined ther-
apy (n = 7). Then, a blood sample (50 µl) was obtained at each checkpoint and stained as previously  described23. 
The percentage and count of memory regulatory T cells (mTregs,  CD3+CD4+CD127lowCD25+CCR4+CD45RO+) 
were analysed weekly throughout the treatment, and total T lymphocyte subsets were analysed at endpoint by 
flow cytometry from peripheral blood samples.
Statistical analysis. Prism 7.0 software (GraphPad software Inc., San Diego, USA) was used to perform the 
statistical analysis. For comparisons of unpaired data, a non-parametric Mann–Whitney test was used and for 
paired comparisons, a non-parametric Wilcoxon test was used.
Ethics statement. This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the Generalitat de Catalunya, Catalan Government. The protocol 
was approved by the Committee on the Ethics of Animal Experiments of the Germans Trias i Pujol Research 
Institute (Permit DAAM 9521) and has followed the principles outlined in the Declaration of Helsinki for ani-
mal experimental investigation. Human samples were obtained after the approval and in strict accordance with 
the recommendations of the guidelines of Germans Trias i Pujol Ethical Committee. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki.
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